Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Accumulated Expenses (2016 - 2026)

Corvus Pharmaceuticals' Other Accumulated Expenses history spans 12 years, with the latest figure at $206000.0 for Q1 2026.

  • Quarterly Other Accumulated Expenses fell 30.41% to $206000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $206000.0 through Mar 2026, down 30.41% year-over-year, with the annual reading at $238000.0 for FY2025, 17.65% down from the prior year.
  • Other Accumulated Expenses came in at $206000.0 for Q1 2026, down from $238000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $566000.0 in Q3 2025 to a low of $131000.0 in Q2 2022.
  • The 5-year median for Other Accumulated Expenses is $238000.0 (2025), against an average of $261411.8.
  • Year-over-year, Other Accumulated Expenses plummeted 66.78% in 2022 and then soared 85.78% in 2023.
  • Corvus Pharmaceuticals' Other Accumulated Expenses stood at $158000.0 in 2022, then skyrocketed by 55.06% to $245000.0 in 2023, then increased by 17.96% to $289000.0 in 2024, then dropped by 17.65% to $238000.0 in 2025, then dropped by 13.45% to $206000.0 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Other Accumulated Expenses are $206000.0 (Q1 2026), $238000.0 (Q4 2025), and $566000.0 (Q3 2025).